Format

Send to

Choose Destination
Circ Res. 2018 May 25;122(11):1586-1607. doi: 10.1161/CIRCRESAHA.118.311597.

Epigenomes in Cardiovascular Disease.

Author information

1
From the Departments of Anesthesiology, Medicine, and Physiology, David Geffen School of Medicine, University of California, Los Angeles.
2
From the Departments of Anesthesiology, Medicine, and Physiology, David Geffen School of Medicine, University of California, Los Angeles. tvondriska@mednet.ucla.edu.

Abstract

If unifying principles could be revealed for how the same genome encodes different eukaryotic cells and for how genetic variability and environmental input are integrated to impact cardiovascular health, grand challenges in basic cell biology and translational medicine may succumb to experimental dissection. A rich body of work in model systems has implicated chromatin-modifying enzymes, DNA methylation, noncoding RNAs, and other transcriptome-shaping factors in adult health and in the development, progression, and mitigation of cardiovascular disease. Meanwhile, deployment of epigenomic tools, powered by next-generation sequencing technologies in cardiovascular models and human populations, has enabled description of epigenomic landscapes underpinning cellular function in the cardiovascular system. This essay aims to unpack the conceptual framework in which epigenomes are studied and to stimulate discussion on how principles of chromatin function may inform investigations of cardiovascular disease and the development of new therapies.

KEYWORDS:

cardiovascular diseases; chromatin; epigenomics; genetics; transcriptome

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center